Osteoporosis International

, Volume 22, Issue 4, pp 1255–1261 | Cite as

Vertebral fractures in Gaucher disease type I: data from the French “Observatoire” on Gaucher disease (FROG)

  • R.-M. Javier
  • E. Hachulla
  • C. Rose
  • V. Gressin
  • P. Chérin
  • E. Noël
  • C. de Roux-Serratrice
  • D. Dobbelaere
  • A. Hartmann
  • R. Jaussaud
  • P. Clerson
  • B. Grosbois
  • C. Roux
Original Article



Gaucher disease type 1 (GD1), results in a range of skeletal complications including osteopenia, osteoporosis, and osteonecrosis, but there is little published information regarding vertebral fractures. Findings from this observational study indicated that the prevalence of vertebral fractures in a cohort of adult French GD1 patients is approximately 15%.


The aim of the study was to assess the prevalence and characteristics of vertebral fractures in a cohort of adult patients with GD1.


This study was performed in adult patients with GD1 based on a detailed and complete clinical examination. For all patients for whom vertebral fractures were reported, a specific questionnaire was sent to physicians, and imaging data were collected, when available, for centralized analysis.


Data were collected from a total of 105 adult GD1 patients. Bone complications were reported in 85% of patients, among whom vertebral fractures were diagnosed in 16 (15%); seven women and nine men (mean age, 45 years). We observed five patients with multiple vertebral fractures and one patient in whom the T3 vertebra was fractured. Most of these patients did not report fracture-related back pain.


The prevalence of vertebral fractures in this cohort of adult patients with GD1 was 15%. Greater awareness of the natural history of vertebral fractures in GD1, and rigorous monitoring of bone fragility and spine involvement in affected patients, should allow earlier detection and initiation of treatment tailored toward improving bone status.


Bone Fracture Gaucher disease Osteopenia Osteoporosis 



We acknowledge the contribution of the following study investigators: Dr. Bauduer; Beauvais: Dr. Themelin; Besançon: Dr. Amsallem; Bois Guillaume: Pr Marie; Bordeaux: Dr. Dumoulin; Bourges: Dr. Steiger, Dr. Mornet; Brest: Dr. Dalbies, Dr. Ianotto; Caen: Dr. Macro; Chatellerault: Dr. Cassan-Faux; Dijon: Pr Solary; Evry: Dr. Denis; Haguenau: Dr. Campos Gazeau; La Rochelle: Dr. Brottier Mancini; La Tronche: Dr. Pegourie; Laval: Dr. Jacomy; Le Kremlin Bicêtre: Dr. Peretti; Libourne: Dr. Ceccaldi; Lille: Dr. Plane; Limoges: Dr. Chaury; Lyon: Dr. Desmurs; Marseille: Pr Harle, Dr. Cohen Valensi; Montpellier: Pr Jorgensen, Dr. Le Quellec, Dr. Vandome; Morlaix: Dr. Robin; Nantes: Dr. Masseau; Nevers: Dr. Djerad; Nice: Dr. Heudier; Paris: Pr Allanore, Dr. Said; Pessac: Dr. Camou; Poitiers: Pr Guilhot Gaudeffroy; Quimper: Dr. Hutin, Dr. Vilque; Reims: Dr. Leone; Rennes: Pr Lamy de la Chapelle; Strasbourg: Dr. Carles, Dr. Benboubker; Tours: Dr. Luca; Vendome: Dr. Amir. Dr. Matthew Reilly of InTouch Medical Ltd. provided editorial assistance on the final draft of this manuscript, sponsored by Actelion Pharmaceuticals.

Conflicts of interest



  1. 1.
    Charrow J, Andersson HC, Kaplan P et al (2000) The Gaucher Registry: demographics and disease characteristics of 1, 698 patients with Gaucher disease. Arch Int Med 160:2835–2843CrossRefGoogle Scholar
  2. 2.
    Kaplan P, Andersson HC, Kacena KA, Yee JD (2006) The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 160:603–608PubMedCrossRefGoogle Scholar
  3. 3.
    Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA (1985) Skeletal complications of Gaucher disease. Medicine (Baltimore) 64:310–322Google Scholar
  4. 4.
    Barak V, Acker M, Nisman B et al (1999) Cytokines in Gaucher’s disease. Eur Cytokine Netw 10:205–210PubMedGoogle Scholar
  5. 5.
    Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324:1464–1470PubMedCrossRefGoogle Scholar
  6. 6.
    Campeau PM, Rafei M, Boivin MN, Sun Y, Grabowski GA, Galipeau J (2009) Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 114:3181–3190PubMedCrossRefGoogle Scholar
  7. 7.
    Charrow J, Dulisse B, Grabowski GA, Weinreb NJ (2007) The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 71:205–211PubMedCrossRefGoogle Scholar
  8. 8.
    DeMayo RF, Haims AH, McRae MC, Yang R, Mistry PK (2008) Correlation of MRI-based bone marrow burden score with genotype and spleen status in Gaucher’s disease. AJR Am J Roentgenol 191:115–123PubMedCrossRefGoogle Scholar
  9. 9.
    Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B (2002) Skeletal aspects of Gaucher disease: a review. Br J Radiol 75(suppl):A2–A12PubMedGoogle Scholar
  10. 10.
    Jaussaud R (2006) The French ‘observatoire’ on Gaucher’s disease. Eur J Int Med 17(Suppl 1):S2–S8Google Scholar
  11. 11.
    Genant HK, Wu CY, vanKuijk C, Nevitt M (1993) Vertebral fracture assessment using a semi-quantitative technique. J Bone Miner Res 8:1137–1148PubMedCrossRefGoogle Scholar
  12. 12.
    Giraldo P, Pocovi M, Perez-Calvo J, Rubio-Felix D, Giralt M (2000) Report of the Spanish Gaucher’s Disease Registry: clinical and genetic characteristics. Heamatologica 85:792–799Google Scholar
  13. 13.
    Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ (2002) Bone complications in children with Gaucher disease. Br J Radiol 75(Suppl 1):A37–44PubMedGoogle Scholar
  14. 14.
    Weinreb NJ, Charrow J, Andersson HC et al (2002) Effectiveness of enzyme replacement therapy in 1, 028 patients with type 1 Gaucher disease after 2–5 years of treatment. A report from the Gaucher registry. Am J Med 113:112–119PubMedCrossRefGoogle Scholar
  15. 15.
    Andersson H, Andersson H, Kaplan P, Kacena K, Yee J (2008) Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 122:1182–1190PubMedCrossRefGoogle Scholar
  16. 16.
    Zimran A, Kay A, Gelbart T et al (1992) Gaucher disease. Clinical, laboratory, radiologic and genetic features of 53 patients. Medicine 71:337–353PubMedCrossRefGoogle Scholar
  17. 17.
    Stirnemann J (2006) Etude clinique de la cohorte française de patients atteints de la maladie de Gaucher. Rev Med Interne 27:S18–S21PubMedCrossRefGoogle Scholar
  18. 18.
    Belmatoug N, Billette de Villemeur T (1995) Skeletal response to enzyme replacement therapy for type 1 Gaucher disease: a preliminary report of the French experience. Semin Hematol 32(Suppl 1):33–38Google Scholar
  19. 19.
    Roca M, Mota J, Alfonso P, Pocoví M, Giraldo P (2007) S-MRI score: a simple method for assessing bone marrow involvement in Gaucher disease. Eur J Radiol 62:132–137PubMedCrossRefGoogle Scholar
  20. 20.
    Katz K, Sabato S, Horev G, Cohen IJ, Yosipovitch Z (1993) Spinal involvement in children and adolescents with Gaucher disease. Spine 18:332–335PubMedCrossRefGoogle Scholar
  21. 21.
    Kocher MS, Hall JE (2000) Surgical management of spinal involvement in children and adolescents with Gaucher's disease. J Pediatr Orthop 20:383–388PubMedCrossRefGoogle Scholar
  22. 22.
    Wiesner L, Niggemeyer O, Kothe R, Meiss L (2003) Severe pathologic compression of three consecutive vertebrae in Gaucher disease: a case report and review of the literature. Eur Spine J 12:97–99PubMedCrossRefGoogle Scholar
  23. 23.
    Ruff ME, Weis LD, Kean JR (1984) Acute thoracic kyphosis in Gaucher's disease. A case report. Spine 9:835–837PubMedCrossRefGoogle Scholar
  24. 24.
    Hill SC, Parker CC, Brady RO, Barton NW (1993) MRI of multiple platyspondyly in Gaucher disease: response to enzyme replacement therapy. J Comput Assist Tomogr 17:806–809PubMedCrossRefGoogle Scholar
  25. 25.
    Grosbois B, Rose C, Gressin V et al (2009) Gaucher disease and monoclonal gammopathy: a report of 17 cases and impact of therapy. Blood Cells Mol Dis 43:138–139PubMedCrossRefGoogle Scholar
  26. 26.
    Goldblatt J, Keet P, Dall D (1987) Spinal cord decompression for Gaucher's disease. Neurosurgery 21:227–230PubMedCrossRefGoogle Scholar
  27. 27.
    Sims KB, Pastores GM, Weinreb NJ et al (2008) Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 73:430–440PubMedCrossRefGoogle Scholar
  28. 28.
    de Fost M, van Noesel CJ, Aerts JM, Maas M, Pöll RG, Hollak CE (2008) Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica 93:1119–1120PubMedCrossRefGoogle Scholar
  29. 29.
    Wenstrup RJ, Bailey L, Grabowski GA et al (2004) Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 104:1253–1257PubMedCrossRefGoogle Scholar
  30. 30.
    Pastores GM, Elstein D, Hrebícek M, Zimran A (2007) Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther 29:1645–1654PubMedCrossRefGoogle Scholar
  31. 31.
    Lebel E, Dweck A, Foldes AJ et al (2004) Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab 22:597–601PubMedCrossRefGoogle Scholar
  32. 32.
    Wenstrup RJ, Kacena KA, Kaplan P et al (2007) Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 22:119–126PubMedCrossRefGoogle Scholar
  33. 33.
    Weinreb N, Barranger J, Packman S et al (2007) Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 71:576–588PubMedCrossRefGoogle Scholar
  34. 34.
    Pastores GM, Weinreb NJ, Aerts H et al (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41(Suppl 5):4–14PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010

Authors and Affiliations

  • R.-M. Javier
    • 1
  • E. Hachulla
    • 2
  • C. Rose
    • 3
  • V. Gressin
    • 4
  • P. Chérin
    • 5
  • E. Noël
    • 6
  • C. de Roux-Serratrice
    • 7
  • D. Dobbelaere
    • 8
  • A. Hartmann
    • 9
  • R. Jaussaud
    • 10
  • P. Clerson
    • 11
  • B. Grosbois
    • 12
  • C. Roux
    • 13
  1. 1.Department of RheumatologyHôpital de HautepierreStrasbourgFrance
  2. 2.Médecine InterneHôpital Claude HuriezLilleFrance
  3. 3.HématologieHôpital St Vincent de PaulLilleFrance
  4. 4.Actelion Pharmaceuticals FranceParisFrance
  5. 5.Médecine InterneHôpital Pitié-SalpêtrièreParisFrance
  6. 6.Médecine InterneHôpital CivilStrasbourgFrance
  7. 7.Médecine InterneHôpital de la TimoneMarseilleFrance
  8. 8.PédiatrieHôpital Jeanne de FlandreLilleFrance
  9. 9.NeurologieHôpital Pitié-SalpêtrièreParisFrance
  10. 10.Médecine Interne et Maladies InfectieusesHôpital Robert DebréReimsFrance
  11. 11.OrgamétrieRoubaixFrance
  12. 12.Médecine InterneEtablissements Nord Sud-Site Hôpital SudRennesFrance
  13. 13.Université Paris DescartesHôpital CochinParisFrance

Personalised recommendations